Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.

ABSTRACT:

Objective

Cemiplimab, a novel PD-1 inhibitor, exhibits significant antitumor activity against advanced non-small cell lung cancer (NSCLC). However, the cost-effectiveness of this drug for the treatment remains unclear. This study aimed to assess the cost-effectiveness of cemiplimab plus chemotherapy compared to chemotherapy for the treatment of advanced NSCLC, from the perspective of the United States payer.

Methods

A partitioned survival approach was developed to project the disease progression of NSCLC. Overall survival (OS) and progression-free survival (PFS) data were obtained from the EMPOWER lung 3 trial and extrapolated to estimate long-term survival outcomes. Direct medical costs and utility data were collected. The primary outcome measure, the incremental cost-utili

SUBMITTER: Lang Y 

PROVIDER: S-EPMC10880349 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature